Search results (1320)
« Back to PublicationsEfficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma
Middleton M. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, 8 - 8
Richter's syndrome of the brain and the spinal cord.
Graves TD. et al, (2011), J Neurol Neurosurg Psychiatry, 82, 943 - 944
A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma.
Medd PG. et al, (2011), Cytometry B Clin Cytom, 80, 230 - 237
A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma
Medd PG. et al, (2011), Cytometry Part B - Clinical Cytometry, 80 B, 230 - 237
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater
Neoptolemos JP. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.
Khan OA. et al, (2011), Br J Cancer, 104, 1822 - 1827
Adverse reactions to Patent Blue v dye used in sentinel lymph node biopsy for Melanoma
Rughani MG. et al, (2011), European Journal of Plastic Surgery, 34, 201 - 204
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
Barsam SJ. et al, (2011), Blood, 117, 5723 - 5732
Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.
Wang DD. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater
Neoptolemos JP. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.
Leijen S. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
Macaulay VM. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D. et al, (2011), Clin Cancer Res, 17, 3420 - 3430
Does metabolic response at repeat PET/CT examination predict pathological response to neoadjuvant chemotherapy in oesophageal cancer?
Gillies RS. et al, (2011), BRITISH JOURNAL OF SURGERY, 98, 7 - 7
METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM
Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22, 31 - 31
METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM
Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22